SARS Coronavirus-2 Microneutralisation and Commercial Serological Assays Correlated Closely for Some but Not All Enzyme Immunoassays
Open Access
- 4 February 2021
- Vol. 13 (2), 247
- https://doi.org/10.3390/v13020247
Abstract
Serological testing for SARS-CoV-2-specific antibodies provides important research and diagnostic information relating to COVID-19 prevalence, incidence and host immune response. A greater understanding of the relationship between functionally neutralising antibodies detected using microneutralisation assays and binding antibodies detected using scalable enzyme immunoassays (EIA) is needed in order to address protective immunity post-infection or vaccination, and assess EIA suitability as a surrogate test for screening of convalescent plasma donors. We assessed whether neutralising antibody titres correlated with signal cut-off ratios in five commercially available EIAs, and one in-house assay based on expressed spike protein targets. Sera from recovered patients or convalescent plasma donors who reported laboratory-confirmed SARS-CoV-2 infection (n = 200), and negative control sera collected prior to the COVID-19 pandemic (n = 100), were assessed in parallel. Performance was assessed by calculating EIA sensitivity and specificity with reference to microneutralisation. Neutralising antibodies were detected in 166 (83%) samples. Compared with this, the most sensitive EIAs were the Cobas Elecsys Anti-SARS-CoV-2 (98%) and Vitros Immunodiagnostic Anti-SARS-CoV-2 (100%), which detect total antibody targeting the N and S1 antigens, respectively. The assay with the best quantitative relationship with microneutralisation was the Euroimmun IgG. These results suggest the marker used (total Ab vs. IgG vs. IgA) and the target antigen are important determinants of assay performance. The strong correlation between microneutralisation and some commercially available assays demonstrates their potential for clinical and research use in assessing protection following infection or vaccination, and use as a surrogate test to assess donor suitability for convalescent plasma donation.Keywords
This publication has 34 references indexed in Scilit:
- Severe Acute Respiratory Syndrome Coronavirus 2−Specific Antibody Responses in Coronavirus Disease PatientsEmerging Infectious Diseases, 2020
- Clinical performance of different SARS‐CoV‐2 IgG antibody testsJournal of Medical Virology, 2020
- Serology assays to manage COVID-19Science, 2020
- Laboratory Testing Methods for Novel Severe Acute Respiratory Syndrome-Coronavirus-2 (SARS-CoV-2)Frontiers in Cell and Developmental Biology, 2020
- Brief clinical evaluation of six high-throughput SARS-CoV-2 IgG antibody assaysJournal of Clinical Virology, 2020
- Evaluation of the EUROIMMUN Anti-SARS-CoV-2 ELISA Assay for detection of IgA and IgG antibodiesJournal of Clinical Virology, 2020
- Developing antibody tests for SARS-CoV-2The Lancet, 2020
- Neutralization of Virus Infectivity by Antibodies: Old Problems in New PerspectivesAdvances in Biology, 2014
- Chronological evolution of IgM, IgA, IgG and neutralisation antibodies after infection with SARS-associated coronavirusClinical Microbiology & Infection, 2004
- Arthropod-Borne Virus Plaques in Agar Overlaid Tube Cultures.Experimental Biology and Medicine, 1959